BioWorld

Nov. 23, 2009

View Archived Issues

SPAs on the Rise for Many, Despite Setbacks for a Few

Twice this month, biotechs that achieved their primary endpoints in a pivotal trial conducted under a special protocol assessment (SPA) found their drugs turned down by the FDA. Read More

Of Vivus and Viagra: Could Patent Expiry Rattle ED Bid?

Read More

Money Raised Year to Date

Read More

Money Raised By Biotech in 2009

Read More

Week in Review

Read More

Word on the Street

Read More

Biotechnology Company Deals With Other Biotechnology Companies: October 1 - November 19, 2009

Read More

Manufacturing, Marketing And Distribution Agreements Between Biotech Companies: October 1 - November 19, 2009

Read More

Biotech - Biotech Collaborations: Modified Agreements: October 1 - November 19, 2009

Read More

Stock Gainers and Losers For The Week

Read More

BioWorld Stock Report For Public Biotechnology Companies

Read More